Ashland
ASH
72.40
-1.72
-2.32%
Ashland
US · ASH
#2461 by market cap
Listed 1970
72.40
-1.72
-2.32%
Periodic snapshot; not a real-time feed.
· 2026-11-20 19:30
✦ Quant Revenue Concentration how this is computed
Diversified
- Life sciences is the largest reported line at 36.22% of revenue, across 5 reported segments.
- No single line clears half of revenue; Personal Care is next at 31.19%, spreading the business across more than one real driver.
Revenue annual, last 8 years
Latest year +2.14% YoY
Margins
- Gross margin
- 32.26%
- Operating margin
- 5.85%
- Net margin
- 0.21%
Key ratios & quality
- Enterprise valuei
- 4.22B
Income statement
| Line item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 2.15B | 2.02B | 2.11B | 2.39B | 2.19B | 2.11B | 1.82B | 1.86B |
| Gross profit | 651.00M | 599.00M | 670.00M | 830.00M | 668.00M | 618.00M | 549.00M | 601.00M |
| Selling & admin expenses | 426.00M | 400.00M | 358.00M | 393.00M | 365.00M | 404.00M | 344.00M | 377.00M |
| Research & development | 58.00M | 56.00M | 50.00M | 55.00M | 51.00M | 55.00M | 54.00M | 55.00M |
| Operating profit | 82.00M | 59.00M | 172.00M | 288.00M | 159.00M | 83.00M | 88.00M | 109.00M |
| Pretax profit | -9.00M | -577.00M | 135.00M | 206.00M | 160.00M | -24.00M | -809.00M | 69.00M |
| Tax | 30.00M | -22.00M | -38.00M | 25.00M | -8.00M | -223.00M | 13.00M | 44.00M |
| Net profit | 505.00M | -508.00M | 220.00M | 927.00M | 178.00M | 169.00M | -845.00M | 4.00M |
| Basic EPS | 8 | -8 | 4 | 17 | 3 | 3 | -18 | 0 |
| Diluted EPS | 8.15 | -8.39 | 3.59 | 16.41 | 3.31 | 3.36 | -18.23 | 0.09 |
| Line item | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 | 2026-09 |
|---|---|---|---|---|---|---|
| Revenue | 463.00M | 477.00M | 386.00M | 482.00M | 497.00M | 498.00M |
| Gross profit | 132.00M | 159.00M | 105.00M | 147.00M | 170.00M | 179.00M |
| Selling & admin expenses | 106.00M | 76.00M | 86.00M | 79.00M | 99.00M | 113.00M |
| Research & development | 13.00M | 13.00M | 13.00M | 14.00M | 15.00M | 14.00M |
| Operating profit | -2.00M | 54.00M | -9.00M | 39.00M | 41.00M | 38.00M |
| Pretax profit | -704.00M | 65.00M | -15.00M | 20.00M | 56.00M | 9.00M |
| Tax | 15.00M | 32.00M | -1.00M | 5.00M | 15.00M | 26.00M |
| Net profit | -742.00M | 32.00M | -12.00M | 16.00M | 16.00M | -16.00M |
| Basic EPS | -16 | 1 | 0 | 0 | 0 | 0 |
| Diluted EPS | -16.21 | 0.70 | -0.26 | 0.34 | 0.35 | -0.35 |
Balance sheet
| Line item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Total current assets | 1.43B | 1.55B | 1.72B | 1.77B | 1.51B | 1.20B | 1.21B | 1.34B |
| Cash & ST investments | 232.00M | 454.00M | 210.00M | 646.00M | 417.00M | 300.00M | 215.00M | 480.00M |
| Inventory | 597.00M | 506.00M | 473.00M | 629.00M | 626.00M | 545.00M | 568.00M | 482.00M |
| Total assets | 7.25B | 6.88B | 6.61B | 6.21B | 5.94B | 5.65B | 4.61B | 4.53B |
| Total current liabilities | 757.00M | 813.00M | 934.00M | 553.00M | 456.00M | 490.00M | 423.00M | 452.00M |
| Short-term debt | 166.00M | 302.00M | 397.00M | 19.00M | 38.00M | 20.00M | 21.00M | 22.00M |
| Long-term debt | 1.50B | 1.57B | 1.60B | 1.27B | 1.31B | 1.35B | 1.38B | 1.37B |
| Total liabilities | 3,680,000,000.00 | 3,841,000,000.00 | 3,860,000,000.00 | 2,993,000,000.00 | 2,842,000,000.00 | 2,777,000,000.00 | 2,707,000,000.00 | 2,679,000,000.00 |
| Total equity | 3.57B | 3.04B | 2.75B | 3.22B | 3.10B | 2.87B | 1.90B | 1.85B |
| Retained earnings | 3.22B | 2.65B | 2.80B | 3.65B | 3.60B | 3.32B | 2.30B | -- |
| Line item | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 | 2026-09 |
|---|---|---|---|---|---|---|
| Total current assets | 1.12B | 1.21B | 1.15B | 1.21B | 1.29B | 1.34B |
| Cash & ST investments | 207.00M | 215.00M | 304.00M | 343.00M | 440.00M | 480.00M |
| Inventory | 567.00M | 568.00M | 565.00M | 506.00M | 490.00M | 482.00M |
| Total assets | 4.62B | 4.61B | 4.52B | 4.50B | 4.58B | 4.53B |
| Total current liabilities | 420.00M | 423.00M | 366.00M | 395.00M | 424.00M | 452.00M |
| Short-term debt | 19.00M | 21.00M | 19.00M | 19.00M | 18.00M | 22.00M |
| Long-term debt | 1.38B | 1.38B | 1.39B | 1.37B | 1.37B | 1.37B |
| Total liabilities | 2,732,000,000.00 | 2,707,000,000.00 | 2,641,000,000.00 | 2,633,000,000.00 | 2,708,000,000.00 | 2,679,000,000.00 |
| Total equity | 1.89B | 1.90B | 1.88B | 1.87B | 1.87B | 1.85B |
| Retained earnings | 2.29B | 2.30B | 2.27B | 2.26B | 2.26B | -- |
Cash flow
| Line item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | 241.00M | 203.00M | 560.00M | -213.00M | 243.00M | 411.00M | 94.00M | 339.00M |
| Depreciation & amortization | 277.00M | 235.00M | 244.00M | 241.00M | 243.00M | 274.00M | 237.00M | 185.00M |
| Free cash flow | 94.00M | 70.00M | 455.00M | -326.00M | 73.00M | 274.00M | -4.00M | 251.00M |
| Dividends paid | -64.00M | -66.00M | -70.00M | -70.00M | -76.00M | -78.00M | -76.00M | -76.00M |
| Stock buybacks / issuance | -200.00M | 0 | -450.00M | -200.00M | -300.00M | -380.00M | -100.00M | 0 |
| Ending cash balance | 232.00M | 454.00M | 210.00M | 646.00M | 417.00M | 300.00M | 215.00M | 480.00M |
| Line item | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 | 2026-09 |
|---|---|---|---|---|---|---|
| Operating cash flow | 106.00M | 27.00M | 109.00M | 41.00M | 114.00M | 75.00M |
| Depreciation & amortization | 76.00M | 50.00M | 48.00M | 45.00M | 48.00M | 45.00M |
| Free cash flow | 86.00M | -7.00M | 95.00M | 24.00M | 94.00M | 38.00M |
| Dividends paid | -19.00M | -19.00M | -19.00M | -19.00M | -19.00M | -19.00M |
| Stock buybacks / issuance | 0 | 0 | -- | -- | 0 | 0 |
| Ending cash balance | 207.00M | 215.00M | 304.00M | 343.00M | 440.00M | 480.00M |
Returns & efficiency
| Line item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| ROE %i | 14.48 | -15.38 | 7.60 | 31.04 | 5.64 | 5.67 | -35.41 | 0.21 |
| ROA %i | 6.51 | -7.19 | 3.26 | 14.46 | 2.93 | 2.92 | -16.48 | 0.09 |
| ROIC %i | 10.50 | -8.23 | 5.45 | 20.68 | 4.57 | 4.52 | -20.78 | 0.12 |
| 5-year avg ROE %i | 5.26 | 0.31 | 2.02 | 8.22 | 8.68 | 6.91 | 2.91 | -- |
| EBIT margin %i | 7.38 | -17.84 | 9.66 | 11.21 | 9.77 | 1.37 | -41.01 | 5.85 |
| FCF / sales %i | 3.49 | 2.79 | 21.55 | -- | 3.33 | 12.97 | -- | 13.47 |
| Current ratioi | 1.89 | 1.90 | 1.84 | 3.20 | 3.30 | 2.44 | 2.85 | 2.96 |
| Quick ratioi | 0.94 | 1.10 | 0.62 | 1.90 | 1.66 | 1.11 | 1.08 | 1.65 |
| Debt / assetsi | 22.99 | 28.92 | 31.81 | 22.26 | 24.55 | 26.01 | 32.31 | 32.52 |
| LT debt / equityi | 42.03 | 55.57 | 61.99 | 42.36 | 45.85 | 50.49 | 77.15 | 78.46 |
| Interest coveragei | 1.61 | -4.72 | 2.96 | 4.32 | 3.96 | 0.55 | -12.26 | -- |
| Revenue CAGR (3Y) %i | -10.73 | -4.42 | -6.58 | 3.64 | 2.81 | 0.03 | -8.63 | -5.26 |
| Net income CAGR (3Y) %i | -- | -- | 24.50 | 22.44 | -- | -8.42 | -- | -71.78 |
| FCF CAGR (3Y) %i | -40.53 | -31.21 | 48.12 | -- | 1.41 | -15.55 | -- | 50.93 |
| Line item | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 | 2026-09 |
|---|---|---|---|---|---|---|
| ROE %i | -35.46 | -35.41 | -30.96 | -31.91 | 2.77 | 0.21 |
| ROA %i | -16.61 | -16.48 | -14.19 | -14.51 | 1.13 | 0.09 |
| ROIC %i | -20.75 | -20.78 | -17.64 | -18.20 | 2.57 | 0.12 |
| 5-year avg ROE %i | -- | -- | -- | -- | -- | -- |
| EBIT margin %i | -42.22 | -41.01 | -30.69 | -31.69 | 10.15 | 5.85 |
| FCF / sales %i | 1.71 | -- | 8.53 | 10.95 | 11.18 | 13.47 |
| Current ratioi | 2.68 | 2.85 | 3.15 | 3.06 | 3.05 | 2.96 |
| Quick ratioi | 0.97 | 1.08 | 1.35 | 1.49 | 1.64 | 1.65 |
| Debt / assetsi | 32.14 | 32.31 | 32.95 | 32.85 | 32.24 | 32.52 |
| LT debt / equityi | 77.61 | 77.15 | 78.27 | 78.19 | 77.97 | 78.46 |
| Interest coveragei | -13.15 | -12.26 | -9.08 | -9.39 | 3.02 | -- |
| Revenue CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
Revenue breakdown most recent period
Business
Life sciences36.22%
Personal Care31.19%
Specialty Additives27.36%
Intermediates7.44%
Quote time 2026-11-20 19:30:06 · For reference only, not investment advice and not tailored to your situation.
Ashland discussion 0 comments